<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609401</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2006-003137-32</org_study_id>
    <secondary_id>EudraCT number 2006-003137-32</secondary_id>
    <nct_id>NCT00609401</nct_id>
  </id_info>
  <brief_title>Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)</brief_title>
  <acronym>ROSORC</acronym>
  <official_title>A Randomized Open Label Multicenter Phase II Study of First Line Therapy With Sorafenib in Association With IL-2 vs Sorafenib Alone in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Trial in Medical Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Trial in Medical Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ROSORC trial is a randomized study comparing the efficacy of a new association (sorafenib
      and IL-2) versus the standard therapy (sorafenib) in patients affected by different
      histotypes of metastatic RCC. This study is a first line therapy for the advanced disease.
      The primary objective is the progression free survival (PFS) in the 2 arms of therapy and the
      secondary objective is the overall survival (OS) and the response rate (RR) and the safety
      profile of the combination compared to sorafenib alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be allocated in 2 groups:

      ARM A - Sorafenib 400 mg twice daily continuously and low dose of IL-2 administered s.c.

      ARM B - Sorafenib alone at the same dosage used in the previous arm

      The trial is stratified according to the MSKCC prognostic model (low intermediate high risk)
      and histology (Clear cell vs other histotypes). The main inclusion criteria are:
      cytohistological diagnosis of RCC, measurable disease as RECIST criteria, signed written
      informed consent, life expectancy of greater than 3 months.

      The efficacy and safety analysis will be performed on an intent to treat population.

      The anticipated median PFS time in the control arm is 6 months and we will expect an increase
      of 3 months in the experimental arm.

      The sample size is 128 patients, 64 in each arm (1:1 randomization)

      The study started in November 2006 and is a multicenter Italian trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Metastatic Disease</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 bid + IL-2 3 MU per 5 day/week for 2 weeks every 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexavar (Sorafenib)</intervention_name>
    <description>400 mg bid</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>IL-2 3 MU per 5 day/week for 2 weeks every 4</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytohistological diagnosis of RCC

          -  Written informed consent

          -  Measurable disease according to RECIST criteria

          -  Age &gt;= 18 years

          -  Karnofsky PS &gt;= 60%

          -  Life expectancy of greater than 3 months

        Exclusion Criteria:

          -  Prior medical treatment for metastatic RCC

          -  Brain metastasis or spinal cord compression

          -  Chronic treatment with corticosteroids

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Procopio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Tumori Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E. Aitini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale di Mantova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Bregni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale San Raffaele Milano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Conti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Urologia - Ospedale di Como</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Maio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Immunologia Oncologica - Ospedale Le Scotte Siena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Fasola, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale di Udine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>V. Zagonel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medicina Oncologica - Ospedale Fatebenefratelli - Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S. Cascinu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale di Ancona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Marini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale di Brescia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Ardizzoia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale di Monza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Ricci, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Oncologia Medica - Ospedale Santa Chiara Pisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>L. Cavanna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oncologia Piacenza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Aglietta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale di Candiolo Torino</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Bertolini, MD</last_name>
    <role>Study Director</role>
    <affiliation>SOC Oncologia Medica Azienda Ospedaliera Valtellina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Bracarda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oncologia Medica Ospedale di Perugia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>L. ISA, MD</last_name>
    <role>Study Director</role>
    <affiliation>A.O. Melegnano - Gorgonzola</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S. Monfardini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oncologia Ospedale di Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D. Amadori, MD</last_name>
    <role>Study Director</role>
    <affiliation>IOR Ospedale di Forl√¨</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Porta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale San Matteo Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.istitutotumori.mi.it</url>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>February 25, 2009</last_update_submitted>
  <last_update_submitted_qc>February 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Giuseppe Procopio</name_title>
    <organization>ITMO</organization>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>RCC</keyword>
  <keyword>Metastatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

